<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00162435</url>
  </required_header>
  <id_info>
    <org_study_id>yc19553-HMO-CTIL</org_study_id>
    <nct_id>NCT00162435</nct_id>
  </id_info>
  <brief_title>Genetic Determinants of Warfarin Anticoagulation Effect</brief_title>
  <official_title>Warfarin Induction Regimen Based Upon CYP2C9, VKORC1 Factor VII Genotyping, PMR and INR Monitoring, as Compared to the Conventional Regimen: a Prospective Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States - Israel Binational Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Israel Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Israel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <brief_summary>
    <textblock>
      The response to warfarin varies greatly among individuals. Some of this variability can be
      ascribed to genetic polymorphisms in the gene encoding for CYP2C9, the enzyme mediating the
      metabolism of S warfarin. In addition genetic polymorphism in other genes (i.e. VKORC1,
      factor VII) have been shown to account for some of the variability in the response to
      warfarin irrespective of CYP2C9.The present study has several segments:

        1. Evaluation of the relationship between genetic polymorphisms in the genes encoding for
           CYP2C9, VKORC1 and factor VII and warfarin maintenance dose at steady state. This study
           is a confirmation of previous data in our own population.

        2. Evaluation of relationship between genetic polymorphisms in the genes encoding for
           CYP2C9, VKORC1 and factor VII and warfarin loading dose during the induction period.

        3. Testing the hypothesis that warfarin loading based on the individual's combined CYP2C9,
           VKORC1 and factor VII genotype may be more efficient and associated with reduced adverse
           drug effects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic end points:</measure>
    <time_frame>1-4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Warfarin clearance and formation clearance of 7-hydroxy-warfarin at steady state</measure>
    <time_frame>1-4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic.</measure>
    <time_frame>1-4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maintenance dose of warfarin at steady state.</measure>
    <time_frame>1-4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach INR &gt; 2.</measure>
    <time_frame>1-4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach pharmacodynamic steady state.</measure>
    <time_frame>1-4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time spent at therapeutic INR &lt;3 and &gt;2.</measure>
    <time_frame>1-4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time spent at INR &gt;3.</measure>
    <time_frame>1-4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time spent at INR &lt;2.</measure>
    <time_frame>1-4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of minor and major bleeding episodes.</measure>
    <time_frame>1-4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Venous Thrombosis</condition>
  <condition>Pulmonary Embolism</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Genetic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <arm_group_label>Genetic</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients in whom warfarin is about to be initiated

          -  Desired therapeutic range &gt;2 and &lt;3

        Exclusion Criteria:

          -  Refusal to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoseph Caraco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yoseph Caraco, MD</last_name>
    <phone>00 972 2 6778584</phone>
    <email>caraco@hadassah.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arik Tzukert, DMD</last_name>
      <phone>00 972 2 6776095</phone>
      <email>arik@hadassah.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Hadas Lemberg, PhD</last_name>
      <phone>00 972 2 6777572</phone>
      <email>lhadas@hadassah.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Yoseph Caraco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2005</study_first_submitted>
  <study_first_submitted_qc>September 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2005</study_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hadassah Medical Organization</investigator_affiliation>
    <investigator_full_name>Yosef Caraco</investigator_full_name>
    <investigator_title>Head, Clinical Pharmacology Unit, Division of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

